Vizient announces that it will present research insights on CAR-T therapy and bone marrow transplants, based on data from its Clinical Database/Resource Manager (CDB/RM™) as part of the 2019 Transplantation & Cellular Therapy Meeting of ASBMT and CIBMTR to be held Feb. 20-24 in Houston.
Vizient will present four posters at the event which is focused on recent progress in basic science, translational research and clinical studies in all areas of blood and marrow transplantation and cellular therapy. The Vizient posters are:
- Emerging Trends in Chimeric Antigen Receptor T-Cell Immunotherapy in Adults from the Vizient CDB/RM. The poster covers a retrospective cohort of 735 patients 18 years and older undergoing CAR-T procedures between October 2017 and August 2018. It describes trends in adult patient populations, outcomes, and adverse events using the CAR-T procedure codes in administrative data. Research and presentation by Alyssa Hartsell Harris, lead analyst at Vizient.
- Emerging Trends in Chimeric Antigen Receptor T-Cell Immunotherapy in Young Adults and Pediatric Patients from the Vizient CDB/RM. The poster covers a retrospective cohort of 40 patients under 25 years undergoing CAR-T procedures between October 2017 and August 2018 and describes trends in young adult patient populations, outcomes and hospitals using the CAR-T procedure codes. Research and presentation by Alyssa Hartsell Harris.
- Resource Utilization in Allogeneic Bone Marrow Harvest Procedures: A Multi-Hospital Perspective. The poster examines the top drivers of cost for more than 5,500 bone marrow extraction encounters in the inpatient and outpatient setting in 2017 using the Vizient CDB/RM. Research by Gwen Ledford, presentation by Sam Hohmann, research analytics director at Vizient.
- Variation in Scope of Practice of Advanced Practice Providers (APPs) Involved in Care of BMT/HCST Patients. The poster is a retrospective cohort study of 63,447 BMT/HSCT encounters at hospitals participating in Vizient’s CDB/RM between Q4 2014 and Q3 2018. The analysis includes a review of advanced practice provider roles, patient demographics, and encounter characteristics. Research and presentation by Sam Hohmann.
“What is unique about the research posters on CAR-T therapies is the freshness of the source data for patient outcomes. This therapy only received ICD-10 codes in October 2017 and CMS data is not yet available. The Vizient CDB has collected 12 months of patient data and we have used that as a base for both posters on this topic,” said Gladys J. Epting, Ph.D., associate vice president, analytics, at Vizient. Additionally, the posters on bone marrow transplants offer new insights into cost drivers for extraction encounters and of care management provided by advanced practice providers.
About Vizient, Inc.
Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2018, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.comas well as our newsroom, blog, Twitter, LinkedIn and YouTube pages for more information about the company.
Source: Vizient, Inc.
A Product Manager with expertise in pharma marketing and sales operations